BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37182159)

  • 1. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
    Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
    Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
    Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis.
    Seidel S; Kowalski T; Nilius-Eliliwi V; Schroers R; Schlegel U
    Neurol Res Pract; 2023 Feb; 5(1):8. PubMed ID: 36814351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2022 Jan; 156(2):307-316. PubMed ID: 34853952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study.
    Ma J; Lin Z; Ding T; Li Q; Zhang M; Kang H; Johnston PB; Ma Y; Chen B
    Front Oncol; 2022; 12():938421. PubMed ID: 35898888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
    Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
    Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
    Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
    Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
    Kuitunen H; Tokola S; Siniluoto T; Isokangas M; Sonkajärvi E; Alahuhta S; Turpeenniemi-Hujanen T; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
    J Neurooncol; 2017 Jan; 131(2):293-300. PubMed ID: 27752883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
    Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
    J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.